Prolocor – a healthcare startup developing an innovative precision diagnostic test with the potential to predict the risk of thrombosis by quantifying FcγRIIa (pFCG test) – recently announced that they have successfully raised $1.7 million in bridge financing. The funding included significant participation by Green Park & Golf Ventures (GPG Ventures) and by the Labcorp Venture Fund.
About 50 million people are living with chronic coronary artery disease in the U.S., Europe, and Japan. And of these, over two million suffer from acute coronary syndrome every year. In each of these cases, the doctor and patient must decide whether to use more powerful therapy to reduce the risk of thrombosis — increasing the risk of bleeding or less-intensive therapy — reducing bleeding risk at the expense of more thrombotic events like heart attack, stroke, and cardiovascular-related death. This prognostic tool being developed by Prolocor will help guide treatment decisions, effectively matching the intensity of therapy with the risk of events.
KEY QUOTES:
“We are encouraged by the impressive progress that the team at Prolocor is making. We look forward to the continued development of this important marker and the results of their ongoing clinical trials.”
– Dr. Clay Heighten, Managing Partner at GPG Ventures
“We have completed the enrollment of our 800 patient acute coronary syndrome (ACS) trial at 25 nationally recognized hospitals and completed an interim analysis of this confirmatory study in September 2023. In addition, our Co-Founder and CSO Dr. David Schneider and his lab team have confirmed the precision, accuracy, and specificity of the unique pCFG test. We sincerely appreciate GPG Ventures and Labcorp’s ongoing support.”
– Dr. Peter DiBattiste, Co-Founder and CEO of Prolocor
“We are very excited about the advancement being made by the Prolocor team and the important work they are doing to advance their innovative test to help predict risk of thrombosis.”
– Megann Vaughn Watters, Vice President, New Venture & Strategic Alliances, Labcorp.
“The Prolocor pFCG test provides powerful prognostic information leveraging a novel approach. The test is performed on fixed platelets removing a major technical limitation of platelet assays.”
– Co-Founder and CSO Dr. David Schneider
